Long Term Safety of 125 mg Per Day of Oral Azimilide in Patients With Implantable Cardioverter Defibrillator (ICDs)
NCT ID: NCT00751738
Last Updated: 2017-02-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
330 participants
INTERVENTIONAL
2002-10-31
2005-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator (ICD) (SHIELD-2)
NCT01464476
Compassionate Use Study of 125 mg Per Day of Azimilide Dihydrochloride in One Patient
NCT00752596
Antiarrythmic Drugs - Long-term Follow-up in the Modern Era
NCT01082055
Evaluation of Two Different Regimens of the Antiarrhythmic Drug Amiodarone to Maintain Normal Sinus Rhythm After Electrical Cardioversion in Patients With Persistent Atrial Fibrillation
NCT07273994
Explorative Study of AZD1305 in Atrial Fibrillation Patients
NCT00643448
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
125 mg azimilide
azimilide dihydrochloride
oral, once daily until sponsor stopped the study
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
azimilide dihydrochloride
oral, once daily until sponsor stopped the study
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* used ticlopidine
* were taking Class I or other Class III drugs
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Forest Laboratories
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Procter and Gamble Pharmaceuticals
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jose M Brum, MD
Role: STUDY_DIRECTOR
Procter and Gamble
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Facility
Mobile, Alabama, United States
Research Facility
Little Rock, Arkansas, United States
Research Facility
La Jolla, California, United States
Research Facility
Loma Linda, California, United States
Research Facility
Sacramento, California, United States
Research Facility
Colorado Springs, Colorado, United States
Research Facility
Bridgeport, Connecticut, United States
Research Facility
Washington D.C., District of Columbia, United States
Research Facility
Fort Lauderdale, Florida, United States
Research Facility
Fort Myers, Florida, United States
Research Facility
Jacksonville, Florida, United States
Research Facility
Maywood, Illinois, United States
Research Facility
Kansas City, Kansas, United States
Research Facility
Portland, Maine, United States
Research Facility
Baltimore, Maryland, United States
Research Facility
Baltimore, Maryland, United States
Research Facility
Boston, Massachusetts, United States
Research Facility
Burlington, Massachusetts, United States
Research Facility
Worcester, Massachusetts, United States
Research Facility
Warren Township, New Jersey, United States
Research Facility
Brooklyn, New York, United States
Research Facility
Johnson City, New York, United States
Research Facility
New York, New York, United States
Research Facility
New York, New York, United States
Research Facility
Rochester, New York, United States
Research Facility
Rochester, New York, United States
Research Facility
West Orange, New York, United States
Research Facility
Williamsville, New York, United States
Research Site
Durham, North Carolina, United States
Research Facility
Winston-Salem, North Carolina, United States
Research Facility
Cincinnati, Ohio, United States
Research Facility
Toledo, Ohio, United States
Research Facility
Tulsa, Oklahoma, United States
Research Facility
Erie, Pennsylvania, United States
Research Facility
Hershey, Pennsylvania, United States
Research Facility
Lancaster, Pennsylvania, United States
Research Facility
Philadelphia, Pennsylvania, United States
Research Facility
Charleston, South Carolina, United States
Research Site
Columbia, South Carolina, United States
Research Facility
Germantown, Tennessee, United States
Research Facility
Nashville, Tennessee, United States
Research Facility
Dallas, Texas, United States
Research Facility
Dallas, Texas, United States
Research Facility
Houston, Texas, United States
Research Facility
Salt Lake City, Utah, United States
Research Facility
Charlottesville, Virginia, United States
Research Facility
Fairfax, Virginia, United States
Research Facility
Spokane, Washington, United States
Research Facility
Green Bay, Wisconsin, United States
Research Facility
Milwaukee, Wisconsin, United States
Research Facility
Bruges, , Belgium
Research Facility
Mont Godinne, , Belgium
Research Facility
Victoria, British Columbia, Canada
Research Facility
St. John's, Newfoundland and Labrador, Canada
Research Site
Halifax, Nova Scotia, Canada
Research Facility
Hamilton, Ontario, Canada
Research Facility
Ottawa, Ontario, Canada
Research Facility
Toronto, Ontario, Canada
Research Facility
Montreal, Quebec, Canada
Research Facility
Québec, , Canada
Research Facility
Lille, , France
Research Facility
Nantes, , France
Research Facility
Paris, , France
Research Facility
Pessac, , France
Research Facility
Tours, , France
Research Facility
Bad Bevensen, , Germany
Research Facility
Berlin, , Germany
Research Facility
Brandenburg, , Germany
Research Facility
Coburg, , Germany
Research Facility
Frankfurt, , Germany
Research Facility
Freiburg im Breisgau, , Germany
Research Facility
Hamburg, , Germany
Research Facility
Heidelberg, , Germany
Research Facility
Ludwigshafen, , Germany
Research Facility
Magdeburg, , Germany
Research Facility
Mannheim, , Germany
Research Facility
Tübingen, , Germany
Research Facility
Gdansk, , Poland
Research Facility
Katowice, , Poland
Research Facility
Lublin, , Poland
Research Facility
Szczecin, , Poland
Research Facility
Warsaw, , Poland
Research Facility
Barcelona, , Spain
Research Facility
Madrid, , Spain
Research Facility
Málaga, , Spain
Research Facility
Valencia, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2001060
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.